Patents by Inventor Antonio Lanzavecchia

Antonio Lanzavecchia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210087257
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: September 3, 2020
    Publication date: March 25, 2021
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • Publication number: 20210009661
    Abstract: This disclosure relates to binding agents with specificity for HIV and to methods for using the same to treat, pre-vent and/or ameliorate HIV infection and/or AIDS.
    Type: Application
    Filed: June 26, 2020
    Publication date: January 14, 2021
    Applicants: Centre Hospitalier Universitaire Vaudois, Institute for Research in Biomedicine
    Inventors: Giuseppe Pantaleo, Antonio Lanzavecchia
  • Patent number: 10889632
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: January 12, 2021
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Publication number: 20200392187
    Abstract: Disclosed herein are nanostructures and their use, where the nanostructures include (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide; wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructures; and wherein the nanostructure displays multiple copies of one or more paramyxovirus and/or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.
    Type: Application
    Filed: April 3, 2018
    Publication date: December 17, 2020
    Inventors: Neil P. KING, David BAKER, Brooke NICKERSON, Lance Joseph STEWART, Laurent PEREZ, Antonio LANZAVECCHIA, Jessica MARCANDALLI
  • Publication number: 20200362026
    Abstract: The present invention provides multispecific antibodies, and antigen binding fragments thereof, that potently neutralize a cytokine and that may thus be useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases. In particular, the present invention provides a multispecific antibody, or an antigen binding fragment thereof, comprising at least two different domains specifically binding to at least two different, non-overlapping sites in a cytokine and an Fc moiety. The invention also relates to nucleic acids that encode such antibodies and antibody fragments and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of inflammatory and/or autoimmune diseases.
    Type: Application
    Filed: November 21, 2019
    Publication date: November 19, 2020
    Inventors: Davide Corti, Antonio Lanzavecchia, Luca Piccoli
  • Patent number: 10815294
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: October 27, 2020
    Assignee: INSTITUTE FOR RESEARCH IN BIOMEDICINE
    Inventor: Antonio Lanzavecchia
  • Publication number: 20200325220
    Abstract: The present invention provides engineered antibodies and antigen binding fragments, in which an additional functional domain is inserted into the elbow region of the antibody or antigen binding fragment. The present invention also provides nucleic acid molecules, such as vectors, encoding such antibodies and antigen binding fragments, host cells and compositions comprising such antibodies, antigen binding fragments or nucleic acid molecules and uses thereof. For example a multispecific antibody format is provided, in which an additional binding site (specificity) is inserted into the elbow region of an antibody or antigen binding fragment.
    Type: Application
    Filed: July 30, 2018
    Publication date: October 15, 2020
    Inventors: Antonio LANZAVECCHIA, Luca PICCOLI
  • Patent number: 10730933
    Abstract: This disclosure relates to binding agents with specificity for HIV and to methods for using the same to treat, prevent and/or ameliorate HIV infection and/or AIDS.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: August 4, 2020
    Assignees: Centre Hospitalier Universitaire Vaudois, Institute For Research In Biomedicine
    Inventors: Giuseppe Pantaleo, Antonio Lanzavecchia
  • Publication number: 20200190169
    Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
    Type: Application
    Filed: November 7, 2019
    Publication date: June 18, 2020
    Inventors: Nicole KALLEWAARD-LELAY, Qing ZHU, Ebony BENJAMIN, Leslie WACHTER, Andy YUAN, Josephine Mary MCAULIFFE, Davide CORTI, Antonio LANZAVECCHIA
  • Publication number: 20200109188
    Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.
    Type: Application
    Filed: October 8, 2019
    Publication date: April 9, 2020
    Inventors: Ebony Benjamin, Nicole Kallewaard-LeLay, Josephine Mary McAuliffe, Frances Palmer-Hill, Leslie Wachter, Andy Yuan, Qing Zhu, Davide Corti, Antonio Lanzavecchia, Barbara Guarino, Anna DeMarco
  • Publication number: 20200093909
    Abstract: The present invention provides a fragment of plasmodium circumsporozoite protein according to SEQ ID NO: 1, for example for use in a malaria vaccine. The present invention also provides nucleic acids encoding a fragment of plasmodium circumsporozoite protein according to SEQ ID NO: 1, compositions comprising a fragment of plasmodium circumsporozoite protein according to SEQ ID NO: 1 and antibodies binding to a fragment of plasmodium circumsporozoite protein according to SEQ ID NO: 1. The antibodies according to the present invention bind specifically to P. falciparum sporozoites and may be used in the treatment and/or prevention of malaria.
    Type: Application
    Filed: April 19, 2018
    Publication date: March 26, 2020
    Inventors: Antonio LANZAVECCHIA, Joshua Hoong Yu TAN, Claudia DAUBENBERGER, Brandon SACK
  • Publication number: 20200048311
    Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.
    Type: Application
    Filed: October 25, 2017
    Publication date: February 13, 2020
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Institute for Research in Biomedicine
    Inventors: Baoshan Zhang, Guillaume Stewart-Jones, Tongqing Zhou, John Mascola, Kai Xu, Yongping Yang, Paul Thomas, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
  • Publication number: 20200017575
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: July 31, 2019
    Publication date: January 16, 2020
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • Publication number: 20200009243
    Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.
    Type: Application
    Filed: September 23, 2019
    Publication date: January 9, 2020
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, Institute for Research in Biomedicine
    Inventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
  • Patent number: 10526404
    Abstract: The present invention provides multispecific antibodies, and antigen binding fragments thereof, that potently neutralize a cytokine and that may thus be useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases. In particular, the present invention provides a multispecific antibody, or an antigen binding fragment thereof, comprising at least two different domains specifically binding to at least two different, non-overlapping sites in a cytokine and an Fc moiety. The invention also relates to nucleic acids that encode such antibodies and antibody fragments and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of inflammatory and/or autoimmune diseases.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: January 7, 2020
    Assignee: INSTITUTE FOR RESEARCH IN BIOMEDICINE
    Inventors: Davide Corti, Antonio Lanzavecchia, Luca Piccoli
  • Patent number: 10519221
    Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: December 31, 2019
    Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SA
    Inventors: Nicole Kallewaard-Lelay, Qing Zhu, Ebony Benjamin, Leslie Wachter, Andy Yuan, Josephine Mary McAuliffe, Davide Corti, Antonio Lanzavecchia
  • Patent number: 10494419
    Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: December 3, 2019
    Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SA
    Inventors: Ebony Benjamin, Nicole Kallewaard-LeLay, Josephine Mary McAuliffe, Frances Palmer-Hill, Leslie Wachter, Andy Yuan, Qing Zhu, Davide Corti, Antonio Lanzavecchia, Barbara Guarino, Anna DeMarco
  • Publication number: 20190345234
    Abstract: This disclosure relates to binding agents with specificity for HIV and to methods for using the same to treat, prevent and/or ameliorate HIV infection and/or AIDS.
    Type: Application
    Filed: December 5, 2016
    Publication date: November 14, 2019
    Applicants: Centre Hospitalier Universitaire Vaudois, Institute for Research in Biomedicine
    Inventors: Giuseppe Pantaleo, Antonio Lanzavecchia
  • Publication number: 20190330277
    Abstract: The present invention provides immunogens comprising a recombinant Respiratory Syncytial Virus (RSV) F protein stabilized in a prefusion conformation and nucleic acids encoding such immunogens. In particular the present invention provides polypeptides, polynucleotides, compositions, and uses thereof for eliciting an immune response to bovine respiratory syncytial virus (bRSV). Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Application
    Filed: December 15, 2017
    Publication date: October 31, 2019
    Inventors: Lei CHEN, Baoshan ZHANG, Peter D. KWONG, Davide CORTI, Antonio LANZAVECCHIA, Geraldine TAYLOR
  • Publication number: 20190307856
    Abstract: The present invention provides novel uses and methods for T cell based immunotherapies. Specifically, the invention relates to novel ligands, targets and nucleic acids and vectors encoding said targets that are useful for modulating T cell responses.
    Type: Application
    Filed: October 12, 2017
    Publication date: October 10, 2019
    Inventors: Roger GEIGER, Antonio LANZAVECCHIA, Federica SALLUSTO